• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

FDA's Generic-Drug Label Rule Draws Controversy

Article

When new evidence emerges that a brand-name prescription drug has harmed patients, manufacturers are required to immediately warn doctors and consumers by updating product labels or sending letters.

When new evidence emerges that a brand-name prescription drug has harmed patients, manufacturers are required to immediately warn doctors and consumers by updating product labels or sending letters.

Drugmakers face major product liability exposure under the “failure to warn” legal theory if they fail to act quickly. That gives them a strong incentive to take prompt steps to protect patient safety.

The federal mandate to update warning labels, however, doesn't apply to the 3.4 billion prescriptions for generic drugs ordered annually in the U.S. In fact, it's just the opposite.

Read the full story here: http://bit.ly/1vwdGj3

Source: Modern Healthcare

Related Videos
Rashon Lane, PhD, MA
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
Dr Sophia Humphreys
Robert Zimmerman, MD
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.